⁶⁸Ga-FAPI PET/CT in cardiac Anderson–Fabry disease: novel insights into disease assessment from a case series

Anderson–Fabry disease (AFD) is an X-linked lysosomal disorder in which cardiac involvement is the main cause of morbidity and mortality, manifesting as left ventricular hypertrophy, heart failure, arrhythmias, and myocardial fibrosis. Myocardial fibrosis is a key pathophysiological process associated with an adverse prognosis. While cardiac magnetic resonance (CMR) identifies established myocardial fibrosis, fibroblast activation protein inhibitor (FAPI) PET enables the molecular assessment of FAP-associated activity. By complementing conventional CMR parameters, including late gadolinium enhancement and native T1 mapping, FAPI PET may improve the characterization and phenotypic classification of cardiac involvement in Anderson–Fabry disease. We report three cases of AFD patients, who underwent Gallium-68–fibroblast activation protein inhibitor (⁶⁸Ga-FAPI) PET-CT as part of a prospective study designed to assess myocardial fibrosis. Overall, ⁶⁸Ga-FAPI uptake closely correlated with CMR findings, reinforcing the role of cardiac fibroblast activation as a relevant pathogenic mechanism in AFD. These findings highlight this new molecular imaging as a promising tool for early detection, risk stratification, and therapeutic guidance in AFD.

Authors

Publication Details

Journal
EJNMMI Reports
Published
2026-11-20
DOI
https://doi.org/10.1186/s41824-026-00337-0
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

⁶⁸Ga-FAPI PET/CT in cardiac Anderson–Fabry disease: novel insights into disease assessment from a case series

Catarina Marques, Elisabete Martins, Paula Soeiro, Teresa Faria et al.
EJNMMI Reports
Lysosomal Storage Disorders Research
article

⁶⁸Ga-FAPI PET/CT in cardiac Anderson–Fabry disease: novel insights into disease assessment from a case series

Catarina Marques, Elisabete Martins, Paula Soeiro, Teresa Faria, Inês Fortuna, Janete Santos, Ana Oliveira, João Paulo Oliveira, Helena Moreira, Mariana Vasconcelos
article en

Abstract

Anderson–Fabry disease (AFD) is an X-linked lysosomal disorder in which cardiac involvement is the main cause of morbidity and mortality, manifesting as left ventricular hypertrophy, heart failure, arrhythmias, and myocardial fibrosis. Myocardial fibrosis is a key pathophysiological process associated with an adverse prognosis. While cardiac magnetic resonance (CMR) identifies established myocardial fibrosis, fibroblast activation protein inhibitor (FAPI) PET enables the molecular assessment of FAP-associated activity. By complementing conventional CMR parameters, including late gadolinium enhancement and native T1 mapping, FAPI PET may improve the characterization and phenotypic classification of cardiac involvement in Anderson–Fabry disease. We report three cases of AFD patients, who underwent Gallium-68–fibroblast activation protein inhibitor (⁶⁸Ga-FAPI) PET-CT as part of a prospective study designed to assess myocardial fibrosis. Overall, ⁶⁸Ga-FAPI uptake closely correlated with CMR findings, reinforcing the role of cardiac fibroblast activation as a relevant pathogenic mechanism in AFD. These findings highlight this new molecular imaging as a promising tool for early detection, risk stratification, and therapeutic guidance in AFD.

EJNMMI ReportsVol. 10(1)
Lysosomal Storage Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon